KRAS and pancreatic adenocarcinoma: With over 90% pancreatic adenocarcinomas harbor oncogenic mutations in KRAS, identification of downstream effectors essential for KRAS-mediated tumorigenicity and drug resistance can lead to new targets of intervention for this intractable disease.